GrandRoundsProstate15TARGET AUDIENCE OVERVIEW OF ACTIVITY Significant interest has been shown in the development of multigene prognostic assays that can evaluate the unique biology of an individual’s cancer to allow for further refinement of risk and subsequently more informed treatment decisions. In recent years a number of novel agents have received FDA approval accompanied by multiple new indications in the disease, and a number of these efforts have proven successful and have yielded therapeutic options that are already available for use in the clinic. As such, additional resources are necessary to assist clinicians as they contend with the complexity of decision-making throughout the course of prostate cancer treatment from localized to advanced metastatic castration-resistant prostate cancer (CRPC). To bridge the gap between research and patient care, this video presentation by Dr Leonard G Gomella uses a review of recent relevant publications and presentations, ongoing clinical trials and clinical investigator treatment preferences to assist urologists, medical and radiation oncologists and other healthcare providers involved in the treatment of prostate cancer with the formulation of up-to-date clinical management strategies. LEARNING OBJECTIVES
ACCREDITATION STATEMENT CME credit is no longer available for this issue CREDIT DESIGNATION STATEMENT CME credit is no longer available for this issue HOW TO USE THIS CME ACTIVITY CME credit is no longer available for this issue CONTENT VALIDATION AND DISCLOSURES FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Presenting Faculty Member Leonard G Gomella, MD Advisory Committee: Abbott Laboratories, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals, Merck; Consulting Agreements: Dendreon Pharmaceuticals Inc, Janssen Biotech Inc, Merck; Contracted Research: Astellas Pharma Global Development Inc. Moderator Judd W Moul, MD Advisory Committee: Bayer HealthCare Pharmaceuticals, Ferring Pharmaceuticals; Contracted Research: Astellas Pharma Global Development Inc; Speakers Bureau: Ferring Pharmaceuticals, Genomic Health Inc, Janssen Biotech Inc, Medivation Inc, Sanofi. Project Steering Committee Members Raoul S Concepcion, MD Advisory Committee, Consulting Agreements and Contracted Research: Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals; Speakers Bureau: Amgen Inc, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals, Dendreon Pharmaceuticals Inc, Genomic Health Inc, Janssen Biotech Inc, MDxHealth Inc, Medivation Inc, Sanofi. Thomas E Keane, MB, ChB Advisory Committee: Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals, Ferring Pharmaceuticals, Janssen Biotech Inc. Adam S Kibel, MD Advisory Committee: Profound Medical Corp; Consulting Agreements: Dendreon Pharmaceuticals Inc, Genomic Health Inc, MTG, Sanofi. Daniel W Lin, MD Contracted Research: Genomic Health Inc, Myriad Genetic Laboratories Inc; Research Grant: Hologic Inc. Neal D Shore, MD Advisory Committee: Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals, Roche Laboratories Inc, Sanofi, Spectrum Pharmaceuticals Inc, Takeda Oncology; Consulting Agreement: Mundipharma International Limited; Contracted Research: Amgen Inc, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals, Genentech BioOncology, Genomic Health Inc, Lilly, Mundipharma International Limited, Roche Laboratories Inc, Sanofi, Spectrum Pharmaceuticals Inc, Takeda Oncology; Speakers Bureau: Bayer HealthCare Pharmaceuticals, Genomic Health Inc. PROJECT CHAIR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc. RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose. This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors. This activity is supported by educational grants from Astellas Pharma Global Development Inc/Medivation Inc, Bayer HealthCare Pharmaceuticals, Dendreon Pharmaceuticals Inc, Genomic Health Inc and Sanofi. Hardware/Software Requirements: Last review date: December 2015 |